panniculitis/tyrosine

Veza se sprema u međuspremnik

ČlanciKlinička ispitivanjaPatenti

Odaberite vrstu sortiranja

12 rezultatima

Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Pyoderma gangrenosum-like necrotizing panniculitis associated with Imatinib: A case report

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Imatinib mesylate is a small tyrosine kinase inhibitor that targets BCR-ABL, ckit and platelet-derived growth factor receptor. It is prescribed by hematologists for chronic myeloid leukemia and acute lymphoblastic leukemia and by oncologists for Gastrointestinal Stromal Tumors (GIST).

Ponatinib-induced neutrophilic panniculitis.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Ponatinib is a bcr-abl tyrosine-kinase inhibitor (TKI) used to treat resistant and refractory chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia that express bcr-abl. Neutrophilic panniculitis has been described in rare cases of patients on other TKIs in the

[Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

BACKGROUND Tyrosine kinase inhibitors are now established as valuable therapy in chronic myelogenous leukaemia (CML). They induce several types of cutaneous side effect, the most common being non-specific maculopapular rash and periocular oedema. Rare cases of panniculitis have been described in

Drug-induced panniculitides.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

A substantial number of all panniculitides fails to recognize a specific etiology, and that is true also for a relatively frequent type of panniculitis, such as erythema nodosum (EN). Between the recognized causative factors of panniculitides, infectious, physical agents, autoimmune mechanisms and

Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Neutrophilic panniculitis is a relatively rare condition, characterized by predominantly neutrophilic inflammation in the subcutaneous fat. Rarely, neutrophilic panniculitis may be induced by chemotherapeutics or targeted molecular therapies, including the Bruton tyrosine kinase inhibitor ibrutinib.

Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major breakthrough in the treatment of chronic lymphocytic leukemia and other B cell malignancies. The first-generation inhibitor ibrutinib works by covalent irreversible binding to BTK, a non-receptor tyrosine kinase of the

Mimicker of necrotising fasciitis with systemic inflammatory response syndrome: recurrent necrotising Sweet's syndrome associated with chronic myelogenous leukaemia.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

A 73-year-old man presented with severe right upper quadrant abdominal pain, overlying erythema, hypotension and fever. CT scan revealed fasciitis and myositis of the right rectus abdominis muscle with subcutaneous inflammation involving the fasciae and muscle. Laboratory studies showed extreme

Insulin resistance and clinical aspects of non-alcoholic steatohepatitis (NASH).

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Non-alcoholic steatohepatitis (NASH) is one of the most common liver disorders. This is highly prevalent in obese and diabetic subjects. Persons with central obesity are at particular risk. Other clinical predictors are age more than 40-50 years and hyperlipidemias, but none of these factors is

A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Recently, a number of medications approved for nondermatologic use have proved useful against dermatologic diseases. This article reviews the dermatologic uses and effects of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops. Deferasirox--an oral iron chelator--could be an effective

Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase (BTK) that is FDA-approved for several lymphoproliferative disorders and chronic GVHD.To characterize cutaneous eruptions arising from ibrutinib and highlight overlap with epidermal growth factor

Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab.

Samo registrirani korisnici mogu prevoditi članke

Prijava Registriraj se

Combination therapy with ibrutinib and cetuximab is being studied in a phase 1b/2 trial in patients with advanced gastrointestinal and genitourinary malignancies. Rash is a common cutaneous adverse effect for both medications. Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for the

Pridružite se našoj
facebook stranici

Herbal & Natural Medicine

Najkompletnija baza ljekovitog bilja potpomognuta znanošću

Radi na 55 jezika
Biljni lijekovi potpomognuti znanošću
Prepoznavanje bilja slikom
Interaktivna GPS karta - označite bilje na mjestu (uskoro)
Pročitajte znanstvene publikacije povezane s vašom pretragom
Pretražite ljekovito bilje po učincima
Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima

Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima